Three doses of Pfizer can protect against Omicron, tests suggest
Three doses of the Pfizer/BioNTech vaccine are likely to protect against infection with the Omicron variant but two doses may not, according to laboratory data.
Tests using antibodies in blood samples have given some of the first insights into how far Omicron escapes immunity, showing a stark drop-off in the predicted protection against infection or any type of disease for people who have had two doses. The findings suggest that, for Omicron, Pfizer/BioNTech should now be viewed as a “three-dose vaccine”.
The vaccine makers said they would continue “at full speed” with plans to develop an updated Omicron-based vaccine by March 2022 if needed – and their working presumption is that it will be.
Read the full story here.